Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid : Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden
BACKGROUND: Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptive treatment. This study estimated incidence proportions and incidence rates of ONJ in cancer patients with bone metastases from solid tumors treated for the prevention of skeletal-related events in routine clinical practice.METHODS: This cohort study in Denmark, Norway, and Sweden in 2011-2018 included 3 treatment coho
